Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Biology · 1efd24fe

Assessment

Why?

Strongest counted support: The RIO trial reported later ART restart and less early rebound in the bNAb arm than the placebo arm. weight 1.800000 evidence

Suppressed as dependent: The passage directly supports delayed rebound and the 45.4 versus 4.6 week ART-restart comparison, but it does not address intact-provirus decline.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Leans supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median...” · 1 claim · 29 September 2026
• “In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median...” · 1 claim · 29 September 2026

Evidence for

• The RIO trial reported later ART restart and less early rebound in the bNAb arm than the placebo arm.

  From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

• Independent coverage reports the RIO antibody arm’s lower early rebound and much later median ART restart than placebo.

  From Use of long-acting broadly neutralizing antibodies may delay HIV rebound following discontinuation of antiretroviral therapy Read 2026-09-29 Relevance STRONG Steps 0 Counted

  Secondary coverage corroborates the principal trial outcomes; the primary paper supplies reservoir details.

• The passage directly supports delayed rebound and the 45.4 versus 4.6 week ART-restart comparison, but it does not address intact-provirus decline.

  From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Supports the trial delay and restart outcomes; intact-provirus clause is not established by this packet excerpt.

Evidence against

None.

Qualifications

• The 68-person cohort comprised predominantly white men who began ART during primary or early-stage HIV infection.

  From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Adds early-treatment and demographic scope.

• The reservoir decline was measured in 22 antibody-arm participants at a mean of 52 weeks, and only intact—not defective—proviruses declined.

  From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Bounds the reservoir result to paired antibody-arm samples at a defined follow-up and distinguishes intact from defective proviruses.

• The reservoir association is correlative and based on a limited number of individuals under specific long-acting antibody exposure.

  From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Records the authors' limitation that the reservoir association is correlative and sample-limited.

Suppressed as dependent

Evidence	Group	Kept instead
33823969		75fc8f57

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

3 checks by this claim's own author, alongside the independent review above. 1 OPPOSING EVIDENCE SEARCH · 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	dd5e8884, 4e48c5be, 75fc8f57, 7d6db54d, f77e294f

Summary

Contribution history

seq	event	detail
16895	APPENDED
16896	ACCEPT	AUTOMATIC_AFTER_VALIDATION
16901	LINK_EVIDENCE	by 1efd24fe (accepted)
16951	LINK_EVIDENCE	by 1efd24fe (accepted)
16963	TASK_RESULT	by 1efd24fe (accepted)
25318	TASK_RESULT	by 1efd24fe (accepted)